Ser14
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser14  -  PSMD11 (mouse)

Site Information
VEFQRAQsLLSTDRE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 468525

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 5 , 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 6 , 12 ) , 'fat, brown' ( 18 ) , 3T3 (fibroblast) [KRas (human), transfection] ( 10 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 2 ) , brain ( 17 , 18 ) , heart ( 1 , 13 , 18 ) , Hepa 1-6 (epithelial) ( 27 ) , hepatocyte ( 1 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 8 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 8 ) , HL-1 (myocyte) ( 8 ) , kidney ( 18 ) , liver ( 3 , 11 , 16 , 18 , 20 , 21 , 23 , 24 , 25 , 26 , 28 ) , liver [leptin (mouse), homozygous knockout] ( 16 ) , lung ( 18 ) , macrophage-bone marrow ( 19 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 19 ) , macrophage-peritoneum ( 15 ) , MC3T3-E1 (preosteoblast) ( 5 ) , MEF (fibroblast) ( 14 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 14 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 14 ) , mpkCCD (renal) ( 1 ) , pancreas ( 18 ) , PYS-2 (epithelial) ( 22 ) , RAW 264.7 (macrophage) ( 7 ) , spleen ( 18 )

Upstream Regulation
Regulatory protein:
KRas (mouse) ( 10 )
Putative in vivo kinases:
PKACA (human) ( 1 )
Treatments:
desmopressin ( 1 ) , fasting ( 1 ) , glucagon ( 1 ) , IL-33 ( 7 ) , insulin ( 12 ) , LPS ( 19 ) , LY294002 ( 12 ) , NKH_477 ( 1 ) , PP1 ( 1 ) , PTH(1-34) ( 5 ) , racepinefrine ( 1 )

Downstream Regulation
Effects of modification on PSMD11:
activity, induced ( 1 )

References 

1

VerPlank JJS, Lokireddy S, Zhao J, Goldberg AL (2019) 26S Proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation. Proc Natl Acad Sci U S A
30782827   Curated Info

2

Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia
28852199   Curated Info

3

Robles MS, Humphrey SJ, Mann M (2017) Phosphorylation Is a Central Mechanism for Circadian Control of Metabolism and Physiology. Cell Metab 25, 118-127
27818261   Curated Info

4

Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250
27841257   Curated Info

5

Williams GR, et al. (2016) Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics. Methods 92, 36-50
26160508   Curated Info

6

Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6
26060331   Curated Info

7

Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44
25367039   Curated Info

8

Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45
25162660   Curated Info

9

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

10

Gnad F, et al. (2013) Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics. Mol Cell Proteomics 12, 2070-80
23608596   Curated Info

11

Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86
23567750   Curated Info

12

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

13

Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11
23737553   Curated Info

14

Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3
23429704   Curated Info

15

Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51
22942356   Curated Info

16

Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83
23140645   Curated Info

17

Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9
22807455   Curated Info

18

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

19

Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371
20531401   Curated Info

20

Possemato A (2010) CST Curation Set: 9729; Year: 2010; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

21

Possemato A (2010) CST Curation Set: 9728; Year: 2010; Biosample/Treatment: tissue, liver/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

22

Zhou J (2010) CST Curation Set: 9675; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

23

Possemato A (2009) CST Curation Set: 8040; Year: 2011; Biosample/Treatment: tissue, liver/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

24

Possemato A (2009) CST Curation Set: 8043; Year: 2011; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

25

Possemato A (2009) CST Curation Set: 8042; Year: 2011; Biosample/Treatment: tissue, liver/AICAR; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

26

Possemato A (2009) CST Curation Set: 8041; Year: 2011; Biosample/Treatment: tissue, liver/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

27

Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46
18846507   Curated Info

28

Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93
17242355   Curated Info